In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fennec Pharmaceuticals Inc.

fennecpharma.com

Latest From Fennec Pharmaceuticals Inc.

Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Financing Innovation

Fennec Banks On EMA’s Seldom-Used PUMA For Sodium Thiosulfate

Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.

Drug Review Europe

Novel Combined Contraceptive Estelle Among Nine New Filings At EMA

Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."

Drug Review Europe

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

US FDA Performance Tracker Drug Delivery
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Otolaryngology
  • Alias(es)
  • Adherex Technologies Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Fennec Pharmaceuticals Inc.
  • Senior Management
  • Rostislav Raykov, CEO
    Robert Andrade, CFO
    Shubh Goel , Chief Commercial Officer
  • Contact Info
  • Fennec Pharmaceuticals Inc.
    Phone: (919) 636-4530
    68 TW Alexander Dr.
    P.O. Box 13628 Research Triangle Park, NC 27709
    USA
UsernamePublicRestriction

Register